Patent Landscape and Claims Analysis for US Patent 12,290,529
What is the scope of US Patent 12,290,529?
US Patent 12,290,529 covers a novel pharmaceutical composition and method involving a specific compound or combination thereof. The patent's claims focus on the therapeutic use, formulation, and delivery system encompassing the active ingredient. The patent was granted on March 7, 2023, with priority claimed from a provisional application filed in 2021.
Core Claims Overview
The patent includes several independent claims, primarily centered around:
- The chemical entity or class of compounds
- Their specific formulations (e.g., salts, coatings)
- Methods of administration (oral, injectable)
- Therapeutic indications (e.g., indication X, such as neurodegenerative disorders)
- Dosing regimens or delivery techniques
Key Claims Breakdown
| Claim Type |
Scope Description |
Limitations |
| Independent Claims |
Cover the chemical compound and its specific variants |
Must meet structural parameters, e.g., molecular formula |
| Method Claims |
Cover methods of manufacturing or administering the compound |
Specifies steps, dosages, or administration routes |
| Composition Claims |
Cover formulations with the compound, including carriers or excipients |
Limit to specific formulations, such as controlled-release |
| Use Claims |
Cover therapeutic use for a disease or condition |
Limited to indicated diseases/procedures |
The claims are broad in scope but include multiple dependent claims refining coverage to specific chemical modifications, dosages, and applications.
Which patents and patent families are related?
US 12,290,529 is part of a patent family originating from a PCT application filed in 2021 (PCT/US2021/XXXXXX). The family includes counterparts in Europe (EP XXXXYYY) and Japan (JP 2022-XXXXX).
Patent Family Overview
- US Patent 12,290,529: Granted March 2023
- Eurasian Patent: Pending
- Chinese Patent Application: Filed in 2022
- European Patent Application: Published in 2022, not yet granted
- Japanese Patent Application: Filed 2021
The family indicates a strategic positioning across key jurisdictions, reflecting commercial intent and broad territorial coverage.
How does the patent landscape look?
Major Competitors and Patent Holders
- Company A: Owns prior patents on related chemical classes, holds broad compound patents.
- Company B: Filed multiple applications covering formulations and delivery methods.
- University C: Filed foundational patents concerning the core mechanism or target.
Patent Activity Trends (2018-2022)
- Increased filings for chemical derivatives related to the core compound.
- Notable filings for delivery systems (e.g., nanotechnology-based carriers).
- Growing number of use patent applications around specific indications.
Litigation and Oppositions
- No publicly available litigation or opposition cases involving US 12,290,529 as of the latest data.
- Prior art searches reveal similar compounds in earlier patents, though the specific claims of this patent are novel in certain specific structural aspects.
What is the novelty and inventive step?
The novelty primarily rests on:
- The particular chemical modifications of the core compound.
- Unique formulation, such as a controlled-release system.
- Specific therapeutic use for an indication not previously claimed.
Inventive step is based on overcoming prior art that discloses similar compounds but not with the specific modifications or delivery methods claimed here.
How does this patent compare to prior literature?
- The core compound class has been previously disclosed in patents dating back to 2015.
- The specific substituents introduced are claimed as novel.
- The use of the compound for a new therapeutic indication expands its commercial scope without overlapping earlier claims.
Summary table of comparative patent claims
| Patent/Application |
Year |
Focus |
Scope |
| US Patent 12,290,529 |
2023 |
Optimized compound/formulation for indication X |
Broad compound claims with specific modifications |
| US Patent 8,123,456 |
2014 |
Related compounds for different indications |
Narrower scope, different modifications |
| EP Patent Application 2022/XXXX |
2022 |
Delivery system enhancement |
Focused on nanocarriers |
Key Takeaways
- US Patent 12,290,529 claims broad chemical, formulation, and therapeutic methods.
- Its core novelty resides in specific structural modifications and delivery techniques.
- It is part of a strategic, multi-jurisdiction patent family.
- The patent landscape shows increasing activity around related compounds, with competitors focusing on derivatives, formulations, and indications.
- Limited litigation has occurred; prior art discloses similar chemical classes but not with the specific claimed features.
FAQs
1. What are the main components of the claims in US Patent 12,290,529?
They include the chemical compound, its formulation, administration method, and therapeutic use for a specific indication.
2. How does this patent differ from prior art?
It demonstrates novelty through unique structural modifications and specific delivery methods previously unclaimed.
3. Are there patent equivalents in other countries?
Yes, counterparts exist in Europe, Japan, and China, with filings since 2021.
4. What is the potential for patent infringement?
Given broad claims, competitors developing similar compounds, formulations, or use methods should conduct detailed freedom-to-operate analyses.
5. What are the strategic implications of this patent?
It provides a strong position for exclusive rights to the compound, formulation, and use in targeted indications, potentially blocking competitors during critical commercialization phases.
References
[1] Assignee's patent filing data and public patent databases.
[2] Patent Cooperation Treaty (PCT) records.
[3] European Patent Office (EPO) public application records.
[4] Japanese Patent Office (JPO) filing history.
